[Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II].
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D001629:Bezafibrate / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004043:Dietary Fiber / Q000627:therapeutic use*; D005260:Female; D005685:Galactans / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D008875:Middle Aged; D053149:Plant Gums
D001053:Apolipoproteins; D004043:Dietary Fiber; D005685:Galactans; D008055:Lipids; D008074:Lipoproteins; D008351:Mannans; D053149:Plant Gums; C007894:guar gum; D001629:Bezafibrate
Einfluss einer kombinierten Verabreichung von Guar-Bezafibrat auf Lipide, Apolipoproteine und Lipoproteine bei Patienten mit primärer Hyperlipoproteinämie Typ II.